Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Prostatic Neoplasms 13Lung Neoplasms 12Carcinoma, Non-Small-Cell Lung 7Breast Neoplasms 7Carcinoma, Renal Cell 6Urinary Bladder Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Neuroblastoma 4Glioblastoma 4Colorectal Neoplasms 4Brain Neoplasms 4Small Cell Lung Carcinoma 3Oropharyngeal Neoplasms 3Neoplasms 3Neoplasm Metastasis 3Mouth Neoplasms 3Melanoma 3Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3Ganglioneuroblastoma 3Disease 3Carcinoma, Hepatocellular 3Carcinoma 3Ureteral Neoplasms 2Rhabdomyosarcoma, Embryonal 2Rhabdomyosarcoma 2Ovarian Neoplasms 2Multiple Myeloma 2Medulloblastoma 2Lymphoma, Mantle-Cell 2

Interventions

lanreotide 1cabozantinib 1X-Rays 1Sunitinib 1Specimen Handling 1Phantoms, Imaging 1Octreotide 1Magnetic Resonance Spectroscopy 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Adenoma, Islet Cell × Magnetic Resonance Spectroscopy × Clear all
NCT03375320 2026-06-03

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

National Cancer Institute (NCI)

Phase 3 Active not recruiting
298 enrolled 14 charts 1 FDA
EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡